This study is looking at a type of personal radiotherapy called Rhenium Skin Cancer Therapy (SCT) for non melanoma skin cancer. Non-melanoma skin cancer incidence rates in England in females are 40% ...

RP1, and other new treatments for non-melanoma skin cancer (NMSC) are available. The market will be driven by the approval of these therapies because it will give patients new and varied treatment ...

If you're in a high-risk group for skin cancer or have been treated for a form of it, familiarize yourself with how it looks. Melanoma is a type of skin cancer. When it spreads to other places ...

Some of the key non-melanoma skin cancer treatments include STP705, AIV001, RP1, SM-020 1% Gel, IFx-Hu2.0, THOR-707, PH-762, and others. Non-melanoma skin cancer (NMSC) encompasses a group of cancers ...

Skin cancer can involve melanocytes, leading to melanoma, but there are other non-melanoma skin cancers. These include basal cell carcinoma, squamous cell carcinoma and, less commonly, Merkel cell ...

Beyond RP1, Replimune is advancing RP2, its second product candidate, for the treatment of metastatic uveal melanoma (MUM) and potentially other rare cancers. A registration-directed study of RP2 ...

The anti-PD1 failed melanoma cohort from the IGNYTE ... The company is also evaluating RP1 in solid organ transplant recipients with skin cancers. RPI, in combination with skin cancer drug Libtayo ...

A confirmatory phase III study of RP1 in combination with Opdivo in advanced melanoma patients who have progressed on anti-PD1 and anti-CTLA-4 therapy, or who are not candidates for anti-CTLA-4 ...

REPL’s RP1 BLA Submission Supported by Robust Study Data Replimune’s BLA submission for RPI, in combination with Bristol Myers’ Opdivo, for the advanced melanoma indication is supported by ...

Replimune, Inc. ($REPL) shares spiked higher in Thursday’s after-hours session after the small-cap biopharma developing oncolytic immunotherapies, provided a key ...